However, with TAVR sales growth falling short of expectations, partly due to hospital staffing shortages seen in the recent past, a slight decline in the valuation multiple is justified. The company reported revenue per share of $9.25 for the last twelve months, and its last three-year average P/S multiple is around 10x, implying a valuation of $92 and over 20% upside from its current levels. Our detailed analysis of Edwards Lifesciences upside post-inflation shock captures trends in the company’s stock during the turbulent market conditions seen over 2022.